Selected research
Industry Research
Antiretroviral Agent Industry Research Report 2026
Market perspective
The global Antiretroviral Agent market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Antiretroviral Agent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Antiretroviral Agent is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Antiretroviral Agent is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Antiretroviral Agent include Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead Sciences, Merck Sharp and Dohme, ViiV Healthcare, AbbVie, GlaxoSmithKline and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Antiretroviral Agent market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antiretroviral Agent Market by Company
Boehringer Ingelheim
Bristol-Myers Squibb
Genentech
Gilead Sciences
Merck Sharp and Dohme
ViiV Healthcare
AbbVie
GlaxoSmithKline
Pfizer
Mylan
Janssen Pharmaceuticals
Antiretroviral Agent Segment by Type
Fusion Inhibitors
Entry Inhibitors—CCR5 Co-Receptor Antagonist
Nucleoside Reverse Transcriptase Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Protease Inhibitors
HIV Integrase Strand Transfer Inhibitors
Others
Antiretroviral Agent Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Others
Antiretroviral Agent Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiretroviral Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antiretroviral Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiretroviral Agent.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antiretroviral Agent manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antiretroviral Agent by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antiretroviral Agent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fusion Inhibitors
- Entry Inhibitors—CCR5 Co-Receptor Antagonist
- Nucleoside Reverse Transcriptase Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Protease Inhibitors
- HIV Integrase Strand Transfer Inhibitors
- Others
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
- Others
Companies covered
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Genentech
- Gilead Sciences
- Merck Sharp and Dohme
- ViiV Healthcare
- AbbVie
- GlaxoSmithKline
- Pfizer
- Mylan
- Janssen Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antiretroviral Agent Market Size (2021-2032)
- 2.2.2 Global Antiretroviral Agent Sales (2021-2032)
- 2.2.3 Global Antiretroviral Agent Market Average Price (2021-2032)
- 2.3 Antiretroviral Agent by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Fusion Inhibitors
- 2.3.3 Entry Inhibitors—CCR5 Co-Receptor Antagonist
- 2.3.4 Nucleoside Reverse Transcriptase Inhibitors
- 2.3.5 Non-Nucleoside Reverse Transcriptase Inhibitors
- 2.3.6 Protease Inhibitors
- 2.3.7 HIV Integrase Strand Transfer Inhibitors
- 2.3.8 Others
- 2.4 Antiretroviral Agent by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Retail Pharmacies
- 2.4.3 Online Pharmacies
- 2.4.4 Hospital Pharmacies
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antiretroviral Agent Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antiretroviral Agent Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Antiretroviral Agent Revenue of Manufacturers (2021-2026)
- 3.4 Global Antiretroviral Agent Average Price by Manufacturers (2021-2026)
- 3.5 Global Antiretroviral Agent Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antiretroviral Agent, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antiretroviral Agent, Product Type & Application
- 3.8 Global Manufacturers of Antiretroviral Agent, Established Date
- 3.9 Global Antiretroviral Agent Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Boehringer Ingelheim
- 4.1.1 Boehringer Ingelheim Company Information
- 4.1.2 Boehringer Ingelheim Business Overview
- 4.1.3 Boehringer Ingelheim Antiretroviral Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Boehringer Ingelheim Antiretroviral Agent Product Portfolio
- 4.1.5 Boehringer Ingelheim Recent Developments
- 4.2 Bristol-Myers Squibb
- 4.2.1 Bristol-Myers Squibb Company Information
- 4.2.2 Bristol-Myers Squibb Business Overview
- 4.2.3 Bristol-Myers Squibb Antiretroviral Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bristol-Myers Squibb Antiretroviral Agent Product Portfolio
- 4.2.5 Bristol-Myers Squibb Recent Developments
- 4.3 Genentech
- 4.3.1 Genentech Company Information
- 4.3.2 Genentech Business Overview
- 4.3.3 Genentech Antiretroviral Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Genentech Antiretroviral Agent Product Portfolio
- 4.3.5 Genentech Recent Developments
- 4.4 Gilead Sciences
- 4.4.1 Gilead Sciences Company Information
- 4.4.2 Gilead Sciences Business Overview
- 4.4.3 Gilead Sciences Antiretroviral Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Gilead Sciences Antiretroviral Agent Product Portfolio
- 4.4.5 Gilead Sciences Recent Developments
- 4.5 Merck Sharp and Dohme
- 4.5.1 Merck Sharp and Dohme Company Information
- 4.5.2 Merck Sharp and Dohme Business Overview
- 4.5.3 Merck Sharp and Dohme Antiretroviral Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Sharp and Dohme Antiretroviral Agent Product Portfolio
- 4.5.5 Merck Sharp and Dohme Recent Developments
- 4.6 ViiV Healthcare
- 4.6.1 ViiV Healthcare Company Information
- 4.6.2 ViiV Healthcare Business Overview
- 4.6.3 ViiV Healthcare Antiretroviral Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 ViiV Healthcare Antiretroviral Agent Product Portfolio
- 4.6.5 ViiV Healthcare Recent Developments
- 4.7 AbbVie
- 4.7.1 AbbVie Company Information
- 4.7.2 AbbVie Business Overview
- 4.7.3 AbbVie Antiretroviral Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AbbVie Antiretroviral Agent Product Portfolio
- 4.7.5 AbbVie Recent Developments
- 4.8 GlaxoSmithKline
- 4.8.1 GlaxoSmithKline Company Information
- 4.8.2 GlaxoSmithKline Business Overview
- 4.8.3 GlaxoSmithKline Antiretroviral Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GlaxoSmithKline Antiretroviral Agent Product Portfolio
- 4.8.5 GlaxoSmithKline Recent Developments
- 4.9 Pfizer
- 4.9.1 Pfizer Company Information
- 4.9.2 Pfizer Business Overview
- 4.9.3 Pfizer Antiretroviral Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Pfizer Antiretroviral Agent Product Portfolio
- 4.9.5 Pfizer Recent Developments
- 4.10 Mylan
- 4.10.1 Mylan Company Information
- 4.10.2 Mylan Business Overview
- 4.10.3 Mylan Antiretroviral Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Mylan Antiretroviral Agent Product Portfolio
- 4.10.5 Mylan Recent Developments
- 4.11 Janssen Pharmaceuticals
- 4.11.1 Janssen Pharmaceuticals Company Information
- 4.11.2 Janssen Pharmaceuticals Business Overview
- 4.11.3 Janssen Pharmaceuticals Antiretroviral Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Janssen Pharmaceuticals Antiretroviral Agent Product Portfolio
- 4.11.5 Janssen Pharmaceuticals Recent Developments
5 Global Antiretroviral Agent Market Scenario by Region
- 5.1 Global Antiretroviral Agent Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antiretroviral Agent Sales by Region: 2021-2032
- 5.2.1 Global Antiretroviral Agent Sales by Region: 2021-2026
- 5.2.2 Global Antiretroviral Agent Sales by Region: 2027-2032
- 5.3 Global Antiretroviral Agent Revenue by Region: 2021-2032
- 5.3.1 Global Antiretroviral Agent Revenue by Region: 2021-2026
- 5.3.2 Global Antiretroviral Agent Revenue by Region: 2027-2032
- 5.4 North America Antiretroviral Agent Market Facts & Figures by Country
- 5.4.1 North America Antiretroviral Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antiretroviral Agent Sales by Country (2021-2032)
- 5.4.3 North America Antiretroviral Agent Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Antiretroviral Agent Market Facts & Figures by Country
- 5.5.1 Europe Antiretroviral Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antiretroviral Agent Sales by Country (2021-2032)
- 5.5.3 Europe Antiretroviral Agent Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Antiretroviral Agent Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antiretroviral Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antiretroviral Agent Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antiretroviral Agent Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antiretroviral Agent Market Facts & Figures by Country
- 5.7.1 South America Antiretroviral Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antiretroviral Agent Sales by Country (2021-2032)
- 5.7.3 South America Antiretroviral Agent Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Antiretroviral Agent Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antiretroviral Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antiretroviral Agent Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antiretroviral Agent Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Antiretroviral Agent Sales by Type (2021-2032)
- 6.1.1 Global Antiretroviral Agent Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Antiretroviral Agent Sales Market Share by Type (2021-2032)
- 6.2 Global Antiretroviral Agent Revenue by Type (2021-2032)
- 6.2.1 Global Antiretroviral Agent Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antiretroviral Agent Revenue Market Share by Type (2021-2032)
- 6.3 Global Antiretroviral Agent Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antiretroviral Agent Sales by Application (2021-2032)
- 7.1.1 Global Antiretroviral Agent Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Antiretroviral Agent Sales Market Share by Application (2021-2032)
- 7.2 Global Antiretroviral Agent Revenue by Application (2021-2032)
- 7.2.1 Global Antiretroviral Agent Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antiretroviral Agent Revenue Market Share by Application (2021-2032)
- 7.3 Global Antiretroviral Agent Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antiretroviral Agent Value Chain Analysis
- 8.1.1 Antiretroviral Agent Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antiretroviral Agent Production Mode & Process
- 8.2 Antiretroviral Agent Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antiretroviral Agent Distributors
- 8.2.3 Antiretroviral Agent Customers
9 Global Antiretroviral Agent Analyzing Market Dynamics
- 9.1 Antiretroviral Agent Industry Trends
- 9.2 Antiretroviral Agent Industry Drivers
- 9.3 Antiretroviral Agent Industry Opportunities and Challenges
- 9.4 Antiretroviral Agent Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst